WuXi NextCODE set to advance precision medicine in China
Partnership between WuXiNextCODE and Fudan Children’s Hospital aims to create national centre of excellence for research, diagnostics, treatment and care.
Genomic diagnostics company WuXiNextCODE have partnered with the Children’s Hospital of Fudan University, Shanghai, to advance precision medicine in China. CHFU serves 2.3 million patients across China, who will gain access to a range of genomic diagnostic tools through the partnership.
The alliance with WuXiNextCODE will give CHFU and its Chinese patients access to CLIA sequencing, scalable informatics and clinical genetic expertise. These sequence-based diagnostics are currently available to patients in the United States and Europe through partnerships with Boston Children’s Hospital and Genomics England.
“We share a mission with CHFU: to put the best technology in the hands of the best doctors and scientists to help patients,” said Dr Ge Li, Chairman and CEO of WuXi AppTec, of which WuXi NextCODE is a wholly owned subsidiary. “We are very excited to join with our friends at CHFU to take the lead in rare disease diagnosis, care and research in China, offering patients world-class testing right here.”
Many genomic service providers are starting to look to China as the next logical progression for their products. Earlier this week Veritas Genetics announced the creation of a Chinese R&D centre in Hangzou that would focus on those conditions that are more prevalent in Asian populations.
“Our aim is to bring our technology into the clinic to deliver precision medicine to patients in every market worldwide,” said Hannes Smarason, President of WuXi NextCODE. “We couldn’t have a better partner than Fudan Children’s for realizing it and giving thousands of young patients and their families the best diagnostics and treatment options for inherited rare disorders.”